H.C. Wainwright Raises the PT on ​CorMedix Inc. (CRMD), Keeps a Buy

​CorMedix Inc. (NASDAQ:CRMD) released fiscal Q3 2025 results connected November 12. The gross for the 4th grew 810.21% year-over-year to $104.28 million, surpassing estimates by $18.25 million. Moreover, the EPS of $1.26 besides topped the statement by $0.63. Revenue maturation was mostly driven by higher-than-expected utilization of DefenCath by the company’s outpatient dialysis customers, contributing $88.8 cardinal to the nett revenue.

​Taking assurance from the results, CorMedix Inc. (NASDAQ:CRMD) raised its full-year pro forma nett gross guidance to a scope of $390 to $410 million, and fourth-quarter nett gross guidance to a scope of $115 to $135 million.

​Analyst Folkes noted that the robust fiscal results were bolstered by the caller acquisition of Melinta, which has helped the institution diversify its business. Moreover, the company’s pipeline besides presents important maturation catalysts, including anticipated results from the Rezzayo survey and the TPN Phase 3 information for DefenCath.

​CorMedix Inc. (NASDAQ:CRMD) is simply a biopharmaceutical institution focused connected processing and commercializing therapeutic products to forestall and dainty life-threatening infectious and inflammatory diseases.

While we admit the imaginable of CRMD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.